21 May 2013
Keywords: Sanofi Pasteur, Sanofi, Vivalis, MAbs, Infectious diseases
Article | 19 January 2012
French biopharma company Vivalis (NYSE Euronext: VLS) says it has extended the agreement signed in 2010 with Sanofi Pasteur, the vaccines ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 January 2012
20 May 2013
© 2013 thepharmaletter.com